NuCana (NASDAQ:NCNA) Issues Quarterly Earnings Results, Beats Estimates By $1,001.64 EPS

NuCana (NASDAQ:NCNA) posted its quarterly earnings results on Thursday. The company reported $999.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $1,001.64, reports.

NuCana Trading Up 5.9%

Shares of NCNA traded up $0.11 during trading hours on Thursday, reaching $1.98. The company had a trading volume of 60,083 shares, compared to its average volume of 29,741. NuCana has a 12-month low of $1.33 and a 12-month high of $40.00. The firm has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $2.79. The company has a market capitalization of $8.24 million, a price-to-earnings ratio of -0.02 and a beta of 2.17.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.